Mohamad Mohty, Head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Sorbonne University, shared a post on X:
“Join us for this unique The International Academy for Clinical Hematology journal club.
Bispecific antibodies are emerging as true game changers in AL amyloidosis, delivering unprecedented efficacy by precisely targeting clonal plasma cells, achieving deep responses, and offering new hope in this once-intractable disease.”
Giada Bianchi, Associate Director of Amyloidosis Program at Brigham and Women’s Hospital, shared a post by Mohamad Mohty on X, adding:
“Thanks for showcasing our work Mohamad Mohty.
We are excited to be able to offer elranatamab to patients with AL amyloidosis through a prospective single arm phase II study at Dana-Farber Cancer Institute and soon in other centers.
Amazing responses thus far.”